Cargando…

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption

Sorafenib significantly improves survival of FLT3-ITD mutated AML patients when used as a post-allogeneic HSCT maintenance. Importantly, clinical trials reported a low rate of toxicities requiring sorafenib discontinuation. The aim of our analysis was to evaluate the real-world experience in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morin, Sarah, Giannotti, Federica, Mamez, Anne-Claire, Pradier, Amandine, Masouridi-Levrat, Stavroula, Simonetta, Federico, Chalandon, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050716/ https://www.ncbi.nlm.nih.gov/pubmed/37007116 http://dx.doi.org/10.3389/fonc.2023.1095870

Ejemplares similares

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2021)

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation
por: Calderin Sollet, Zuleika, et al.
Publicado: (2023)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2016)

T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2022)

Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation
por: Simonetta, Federico, et al.
Publicado: (2019)

When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
por: Roth, Romain Samuel, et al.
Publicado: (2022)

P1357: IMPAIRED CELLULAR RESPONSES AGAINST SARS-COV-2 AFTER COVID-19 INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
por: Mamez, A.-C., et al.
Publicado: (2022)

Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation
por: Pradier, Amandine, et al.
Publicado: (2023)

T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Pradier, A., et al.
Publicado: (2022)

Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
por: Glampedakis, Emmanouil, et al.
Publicado: (2021)

Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation
por: Pradier, Amandine, et al.
Publicado: (2020)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
por: Schmidt, Franziska, et al.
Publicado: (2022)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial
por: Xu, Xin, et al.
Publicado: (2022)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma
por: Zanella, Marie-Céline, et al.
Publicado: (2023)

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
por: Olearo, Flaminia, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
por: Simeunovic, Helena, et al.
Publicado: (2022)

Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3–ITD-mutated acute myeloid leukemia
por: Aydin, Semra, et al.
Publicado: (2022)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies
por: Paiano, Sandra, et al.
Publicado: (2015)

Rhinovirus Infections among Hematopoietic Stem Cell Transplant Recipients: A Pre-Transplant Dilemma?
por: Barral, Sébastien, et al.
Publicado: (2022)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
por: Royston, Léna, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better
por: Rebmann, Ekaterina, et al.
Publicado: (2022)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2021)

Evaluation of FLT3-ITD Mutations and MDR1 Gene Expression in AML Patients
por: Yazdandoust, Ehsan, et al.
Publicado: (2022)

Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study
por: Shao, Ruoyang, et al.
Publicado: (2023)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_94lncaqvp3gblra69mu8fm9e4p